Efaproxiral Sodium

CAS No. 170787-99-2

Efaproxiral Sodium( RSR13 sodium )

Catalog No. M18116 CAS No. 170787-99-2

Efaproxiral Sodium , a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 41 In Stock
50MG 60 In Stock
200MG 129 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Efaproxiral Sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Efaproxiral Sodium , a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer.
  • Description
    Efaproxiral Sodium , a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RSR13 sodium
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    170787-99-2
  • Formula Weight
    363.38
  • Molecular Formula
    C20H23NO4·Na
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 39 mg/mL; 107.33 mM
  • SMILES
    [Na+].Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C([O-])=O)cc2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Donnelly ET, et al. Exp Biol Med (Maywood), 2006, 231(3), 317-321.
molnova catalog
related products
  • Allatostatin IV

    Allatostatin IV, an octapeptide amine, is a member of the allatoregulatory peptide family found in insects which either inhibit (allatostatins) or stimulate (allatotropins) juvenile hormone (JH) synthesis.

  • DSN28369

    DSN28369 is a heterobifunctional linker, and useful to make antibody drug conjuate (ADC).

  • Bryodulcosigenin

    Bryodulcosigenin has anti-inflammatory effect, it shows potent inhibitory effects on EBV-EA induction.